Previous 10 | Next 10 |
home / stock / onc:cc / onc:cc news
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy PR Newswire Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, inclu...
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep Canada NewsWire Updated plan follows PanCAN's strategic re-evaluation of the Precision Promise SM Program PanCAN US$5 million grant provides support for new GOBLET mFOLFIRINOX arm to proceed...
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC Canada NewsWire Novel imaging mass cytometry (IMC) technology enables a closer look at tumor microenvironment post-pelareorep/atezolizumab/letrozole treatment Affirms pe...
Oncolytics Biotech Inc. (ONC:CA) is expected to report $-0.1 for Q3 2023 Enbridge Inc. (ENB:CA) is expected to report $0.59 for Q3 2023 Magna International Inc. (MG:CA) is expected to report $1.86 for Q3 2023 Laramide Resources Ltd. (LAM:CA) is expected to report for Q2 2024 Ensig...
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights PR Newswire Phase 1/2 survival data from GOBLET pancreatic cancer cohort demonstrates improvements over historical control trials Award and grant funding from Pancreatic Ca...
Oncolytics Biotech Inc. (ONC:CA) is expected to report $-0.1 for Q3 2023
2023-10-23 09:45:50 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – October 23, 2023 – USA News Group – Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the onco...
2023-10-23 08:45:38 ET Palm Beach, FL – October 23, 2023 – FinancialNewsMedia.com News Commentary – Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy of both the digestive system and endocrine system with disappointing prognoses. The number of ne...
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO PR Newswire 7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25% T-cell expansion data correlate with tumor response, providing impo...
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study PR Newswire Results met efficacy criteria for enrollment expansion and provide support for pelareorep's mechanism of action SAN DIEGO and CALGARY, AB ...
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONC:CC Stock Symbol:
TSXC Market:
Oncolytics Biotech Inc. Website:
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program PR Newswire Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overall...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence PR Newswire Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...